mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...

Readers are advised this story contains graphic images. She was diagnosed with nodular melanoma, an aggressive form of cancer that can grow and spread quickly. "From that day forward, it's been a ...

指南不一致率及影响因素：研究人员定义的不一致情况，即对 T1a 期黑色素瘤进行 SLNB 或对≥T2a 期黑色素瘤未进行 SLNB，最初发生率为 8.2%。经过对医疗记录的审查，找出可接受的不遵循指南的原因后，该比率降至 1.6%。这一发现揭示了两个关键要点：一方面 ...